The use of SGLT2 inhibitors for cardio-renal protection is known to correct anemia in diabetes, heart failure, chronic kidney disease, and chronic obstructive pulmonary disease [35,36,37,38]. The gene discussed is SLC5A2; the disease is chronic kidney disease.